Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milciclib maleate - Nerviano Medical Sciences

Drug Profile

Milciclib maleate - Nerviano Medical Sciences

Alternative Names: PHA 848125C; PHA-125; PHA-848125; PHA-848125AC; TZLS-201

Latest Information Update: 10 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Tiziana Life Sciences
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Piperazines; Pyrazolones; Quinazolines; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 5 inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Thymoma
  • Phase I/II Glioma
  • Phase I Solid tumours
  • No development reported Mesothelioma

Most Recent Events

  • 03 Dec 2018 Tiziana Life Sciences completes enrolment in its phase IIa trial for Hepatocellular carcinoma in Italy, Israel, Greece and Turkey (NCT03109886)
  • 09 Nov 2018 Pharmacodynamics from preclinical studies in Hepatocellular carcinoma presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2018)
  • 16 Oct 2018 Pharmacodynamics from preclinical studies in Hepatocellular carcinoma (HCC) presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top